Skip to main content
. 2024 Feb 28;13(1):9. doi: 10.1038/s41389-024-00511-8

Fig. 1. PKC inhibitor treatment suppresses MAPK signalling in vivo.

Fig. 1

A Median ssGSEA scores for the Hallmark and MAPK gene sets in 11 UM PRE and EDT tumour biopsies treated with the PKC inhibitor IDE196 monotherapy (n = 5) or with combination IDE196 and the HDM2 inhibitor, HDM201 (n = 6). MAPK signalling gene sets are shown in red, proliferative gene sets in blue and metabolic gene sets in yellow. B Correlation of the proliferative Hallmark_MYC_targets_V2 targets signature (ssGSEA scores) with other gene sets in tumour biopsies of UM patients treated with IDE196 monotherapy (n = 5, black) or with combination IDE196 and the HDM2 inhibitor, HDM201 (n = 6, red). The correlation was calculated using Pearson’s correlation, false discovery rate (FDR)-adjusted P values shown.